Eli Lilly launches oral weight-loss drug Foundayo in UK

Aug. 24 (Reuters) - Eli Lilly LLY.N has launched its pill, Foundayo, in the UK for weight management and type 2 diabetes, it said on Monday, making Britain the first country in Europe where the oral treatment is available.

• The pill, known chemically as orforglipron, will be available via private prescription after Britain's medicines regulator authorised the drug on August 10, making it the second GLP-1 tablet to be launched in the UK after Novo Nordisk's NOVOb.CO Wegovy pill.
• England's health cost-effectiveness watchdog, the National Institute for Health and Care Excellence, must assess the pill before it can become available on the state-run National Health Service.
• Lilly said it was working with NICE during the agency's assessment of Foundayo for weight management access.

• Until then, patients can access the pill through private providers. Foundayo will likely be priced between £100 and £120 ($136 and $164), lower than Lilly's Mounjaro injection's £330 price for a month's supply, the company said.
• Private providers in the UK price the Wegovy weight-loss pill from £74 to £129 per month for initial low doses, with most starting rates tied to multi-month subscription plans. Prices for patients go up as they move to higher doses of the pill.
• Foundayo remains under review in the European Union, while Novo's Wegovy pill has won a positive recommendation from the European Medicines Agency, with a final decision from the European Commission pending.

($1 = 0.7338 pounds)